HK Stock Market Move | BOSIDENG (03998) rose by more than 11%, cooling down is favorable for winter sales, and next year's Spring Festival will extend and increase the peak season limit.
Bosideng (03998) has expanded its gains in the afternoon, as of the time of writing, it has increased by 10.67% to HKD 4.98, with a turnover of HKD 4.99 billion.
BOSIDENG (03998) extended its gains in the afternoon, rising by 10.67% as of the time of publication, reaching 4.98 Hong Kong dollars with a trading volume of 4.99 billion Hong Kong dollars.
On the news front, according to the China Meteorological Administration, over the next two days, the southern areas and the northern part of the South China Sea will experience strong wind and rain due to the combined influence of Typhoon "Fengshen" and its peripheral circulation along with cold air. Meanwhile, as the cold air moves eastward and southward, regions such as Jiangnan and South China will become core areas of temperature drop. Starting tomorrow, various regions in the central and eastern parts of the country will gradually enter a warming trend, but the process will be slow, and around the 25th, there will still be another wave of cold air, making it difficult for temperatures to rise, thus continuous efforts to stay warm are necessary.
Shenwan Hongyuan Group released a research report recommending BOSIDENG at the current point in time. The report points out that the onset of cooling will directly benefit BOSIDENG, which mainly sells winter clothing. The Chinese New Year in 2026 is on February 17, which is 19 days later than in 2025 (January 29), extending the peak sales season and generating additional sales increment, thus raising the upper limit of the peak season. Additionally, the relatively low base in the winter of 2024 is objectively favorable for achieving the sales target. In terms of market style, focus should be placed on high-dividend assets: BOSIDENG has maintained a dividend payout ratio of 80% or higher in the past, and this year's high dividend trend is expected to continue, with optimism on the company's future performance and valuation enhancement.
Related Articles

US Stock Market Move | Halliburton (HAL.US) rose more than 9% with Q3 results exceeding expectations.

ANHUIEXPRESSWAY(00995) plans to invest approximately 3.0187 billion yuan to acquire 7% equity of Shandong Hi-speed(600350.SH)
.png)
Sichuan Biokin Pharmaceutical (688506.SH): Clinical trial of injectable BL-M24D1 (ADC) drug approved.
US Stock Market Move | Halliburton (HAL.US) rose more than 9% with Q3 results exceeding expectations.

ANHUIEXPRESSWAY(00995) plans to invest approximately 3.0187 billion yuan to acquire 7% equity of Shandong Hi-speed(600350.SH)

Sichuan Biokin Pharmaceutical (688506.SH): Clinical trial of injectable BL-M24D1 (ADC) drug approved.
.png)
RECOMMEND

Why European Automakers Are Opposing Dutch Sanctions
20/10/2025

Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025

Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025